Rani Therapeutics Holdings, Inc. (RANI)

Market Cap	195.12M
Revenue (ttm)	n/a
Net Income (ttm)	-33.08M
Shares Out	50.42M
EPS (ttm)	-1.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,417
Open	3.830
Previous Close	3.820
Day's Range	3.789 - 4.000
52-Week Range	1.820 - 8.750
Beta	0.26
Analysts	Strong Buy
Price Target	11.83 (+205.69%)
Earnings Date	Aug 9, 2024

About RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibod...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 140
• Stock Exchange: NASDAQ
• Ticker Symbol: RANI

Analyst Forecast

According to 6 analysts, the average rating for RANI stock is "Strong Buy." The 12-month stock price forecast is $11.83, which is an increase of 205.69% from the latest price.

Price Target

$11.83

(205.69% upside)

Analyst Consensus: Strong Buy